[144] QIAGEN N.V. SEC Filing
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.
Presentata la Form 144 per QGEN segnala la proposta vendita di 25.000 azioni ordinarie sul New York Stock Exchange per un valore di mercato complessivo di $1.220.000 e un capitale sociale circolante di circa 216.834.000 azioni. Le azioni da vendere sono state acquisite come Restricted Stock Unit (RSU) in pi霉 tranche nel 2021 e nel 2022, con lotti da 5.918; 5.247; 5.089; 4.253; e 4.493 azioni. Il dichiarante indica che non sono state vendute azioni negli ultimi tre mesi e conferma di non essere a conoscenza di informazioni sfavorevoli rilevanti non divulgate sull'emittente. L'operazione 猫 pianificata per circa il 15/08/2025.
Form 144 presentada para QGEN informa de la propuesta de venta de 25.000 acciones ordinarias en la Bolsa de Nueva York por un valor de mercado agregado de $1.220.000 y aproximadamente 216.834.000 acciones en circulaci贸n. Los valores a vender se adquirieron como Restricted Stock Units (RSU) en varias fechas de 2021 y 2022, con lotes individuales de 5.918; 5.247; 5.089; 4.253; y 4.493 acciones. El declarante indica que no se vendieron valores en los 煤ltimos tres meses y afirma no tener conocimiento de informaci贸n adversa material no divulgada sobre el emisor. La transacci贸n est谩 prevista aproximadamente para el 15/08/2025.
QGEN鞐� 雽�頃� Form 144 鞝滌稖鞚�(電�) 雺挫殨歃濌秾瓯半灅靻岇棎靹� 齑� 鞁滉皜齑濎暋 $1,220,000鞐� 頃措嫻頃橂姅 氤错喌欤� 25,000欤检潣 毵る弰毳� 鞝滌晥頃滊嫟瓿� 氤搓碃頃╇媹雼�. 氚滍枆欤检嫕靾橂姅 鞎� 216,834,000欤检瀰雼堧嫟. 毵る弰 鞓堨爼 歃濌秾鞚� 2021雲勱臣 2022雲勳棎 鞐煬 彀 Restricted Stock Unit(RSU)鞙茧 旆摑霅� 瓴冹溂搿�, 臧滊硠 氚办箻電� 臧侁皝 5,918; 5,247; 5,089; 4,253; 氚� 4,493欤检瀰雼堧嫟. 鞝滌稖鞛愲姅 斓滉芳 靹� 雼皠 歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢溂氅� 氚滍枆靷棎 甏�頃� 氙戈车臧� 欷戩殧 攵堧Μ 鞝曤炒電� 鞚胳頃橁碃 鞛堨 鞎婋嫟瓿� 頇曥柛頃╇媹雼�. 瓯半灅 鞓堨爼鞚检潃 雽�霝� 2025雲� 8鞗� 15鞚检瀰雼堧嫟.
Form 144 d茅pos茅e pour QGEN signale la proposition de vente de 25 000 actions ordinaires 脿 la Bourse de New York pour une valeur de march茅 totale de 1 220 000 $ et environ 216 834 000 actions en circulation. Les titres 脿 vendre ont 茅t茅 acquis sous forme de Restricted Stock Units (RSU) 脿 plusieurs dates en 2021 et 2022, par lots individuels de 5 918; 5 247; 5 089; 4 253; et 4 493 actions. Le d茅clarant indique qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois et affirme ne pas 锚tre au courant d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur. La transaction pr茅vue est programm茅e aux alentours du 15/08/2025.
Form 144 f眉r QGEN eingereicht meldet einen geplanten Verkauf von 25.000 Stammaktien an der New York Stock Exchange mit einem Gesamtmarktwert von $1.220.000 und rund 216.834.000 ausstehenden Aktien. Die zu ver盲u脽ernden Wertpapiere wurden als Restricted Stock Units (RSU) an mehreren Terminen in 2021 und 2022 erworben, in Einzelpartien von 5.918; 5.247; 5.089; 4.253; und 4.493 Aktien. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben und best盲tigt, keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten zu kennen. Die geplante Transaktion ist f眉r etwa den 15.08.2025 vorgesehen.
- Proposed sale is limited in size: 25,000 shares represent a very small percentage of the 216,834,000 outstanding shares
- Securities originate from RSU awards, showing the lots were issued as compensation rather than acquired in opportunistic transactions
- No sales in the past three months reported by the filer
- None.
Insights
TL;DR: A small, planned insider sale from RSU awards totaling 25,000 shares valued at $1.22M; no recent sales reported.
The filing documents a proposed sale of 25,000 common shares representing roughly 0.0115% of the 216.834M outstanding shares, indicating this is a modest insider liquidity event rather than a large disposition. The lots originated from RSU awards vested on 02/15/2021, 02/28/2022 and 03/31/2022, which supports that the shares are routine compensatory issuances rather than open-market purchases. The filer reports no sales in the prior three months and certifies no undisclosed material adverse information.
TL;DR: Transaction appears procedural and compliant with Rule 144 disclosures; filer gives the standard attestation.
The notice provides required Rule 144 details: class, broker, number of shares, aggregate value, acquisition dates and nature (RSU awards), and an approximate sale date. The inclusion of the filer attestation about lack of undisclosed material information and the absence of recent sales align with standard compliance expectations. No governance red flags or extraordinary departures from disclosure norms are evident in the provided data.
Presentata la Form 144 per QGEN segnala la proposta vendita di 25.000 azioni ordinarie sul New York Stock Exchange per un valore di mercato complessivo di $1.220.000 e un capitale sociale circolante di circa 216.834.000 azioni. Le azioni da vendere sono state acquisite come Restricted Stock Unit (RSU) in pi霉 tranche nel 2021 e nel 2022, con lotti da 5.918; 5.247; 5.089; 4.253; e 4.493 azioni. Il dichiarante indica che non sono state vendute azioni negli ultimi tre mesi e conferma di non essere a conoscenza di informazioni sfavorevoli rilevanti non divulgate sull'emittente. L'operazione 猫 pianificata per circa il 15/08/2025.
Form 144 presentada para QGEN informa de la propuesta de venta de 25.000 acciones ordinarias en la Bolsa de Nueva York por un valor de mercado agregado de $1.220.000 y aproximadamente 216.834.000 acciones en circulaci贸n. Los valores a vender se adquirieron como Restricted Stock Units (RSU) en varias fechas de 2021 y 2022, con lotes individuales de 5.918; 5.247; 5.089; 4.253; y 4.493 acciones. El declarante indica que no se vendieron valores en los 煤ltimos tres meses y afirma no tener conocimiento de informaci贸n adversa material no divulgada sobre el emisor. La transacci贸n est谩 prevista aproximadamente para el 15/08/2025.
QGEN鞐� 雽�頃� Form 144 鞝滌稖鞚�(電�) 雺挫殨歃濌秾瓯半灅靻岇棎靹� 齑� 鞁滉皜齑濎暋 $1,220,000鞐� 頃措嫻頃橂姅 氤错喌欤� 25,000欤检潣 毵る弰毳� 鞝滌晥頃滊嫟瓿� 氤搓碃頃╇媹雼�. 氚滍枆欤检嫕靾橂姅 鞎� 216,834,000欤检瀰雼堧嫟. 毵る弰 鞓堨爼 歃濌秾鞚� 2021雲勱臣 2022雲勳棎 鞐煬 彀 Restricted Stock Unit(RSU)鞙茧 旆摑霅� 瓴冹溂搿�, 臧滊硠 氚办箻電� 臧侁皝 5,918; 5,247; 5,089; 4,253; 氚� 4,493欤检瀰雼堧嫟. 鞝滌稖鞛愲姅 斓滉芳 靹� 雼皠 歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢溂氅� 氚滍枆靷棎 甏�頃� 氙戈车臧� 欷戩殧 攵堧Μ 鞝曤炒電� 鞚胳頃橁碃 鞛堨 鞎婋嫟瓿� 頇曥柛頃╇媹雼�. 瓯半灅 鞓堨爼鞚检潃 雽�霝� 2025雲� 8鞗� 15鞚检瀰雼堧嫟.
Form 144 d茅pos茅e pour QGEN signale la proposition de vente de 25 000 actions ordinaires 脿 la Bourse de New York pour une valeur de march茅 totale de 1 220 000 $ et environ 216 834 000 actions en circulation. Les titres 脿 vendre ont 茅t茅 acquis sous forme de Restricted Stock Units (RSU) 脿 plusieurs dates en 2021 et 2022, par lots individuels de 5 918; 5 247; 5 089; 4 253; et 4 493 actions. Le d茅clarant indique qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois et affirme ne pas 锚tre au courant d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur. La transaction pr茅vue est programm茅e aux alentours du 15/08/2025.
Form 144 f眉r QGEN eingereicht meldet einen geplanten Verkauf von 25.000 Stammaktien an der New York Stock Exchange mit einem Gesamtmarktwert von $1.220.000 und rund 216.834.000 ausstehenden Aktien. Die zu ver盲u脽ernden Wertpapiere wurden als Restricted Stock Units (RSU) an mehreren Terminen in 2021 und 2022 erworben, in Einzelpartien von 5.918; 5.247; 5.089; 4.253; und 4.493 Aktien. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben und best盲tigt, keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten zu kennen. Die geplante Transaktion ist f眉r etwa den 15.08.2025 vorgesehen.
FAQ
What is the size and value of the proposed QGEN sale reported on the Form 144?
When is the approximate sale date listed on the QGEN Form 144?
How many QIAGEN shares are outstanding according to this filing?
What is the origin of the shares being sold in the Form 144?
Were any shares sold by the filer in the past three months?
